Dementia and Alzheimer Disease

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation highlighted the critical role of collaboration and innovative diagnostics for advancing Alzheimer disease care. [WATCH TIME: 4 minutes]

Over 1 year of treatment, simufilam failed to distinguish itself from placebo on the primary end points of Alzheimer’s Disease Assessment Scale-Cognitive Subscale 12 and Alzheimer’s Disease Cooperative Study-Activities of Daily Living.

Here's some of what is coming soon to NeurologyLive® this week.

Jessica Langbaum, PhD, the senior director of research strategy at Banner Alzheimer’s Institute, discussed the challenges and opportunities in improving diversity in Alzheimer disease clinical trials.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 22, 2024.

The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Over a 12-month treatment period, patients on deferiprone demonstrated decreased blood ferritin and hippocampal QSM but caused accelerated cognitive decline and increased regional brain atrophy.

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

The associate professor of neurology at Georgetown University provided clinical insight on the origins of nilotinib and its medicinal promise in treating patients with Dementia with Lewy bodies, a neurodegenerative disorder.

The change in opinion was after reconsidering the totality of data from the phase 3 Clarity AD trial, a large-scale study of lecanemab featuring more than 1500 patients with early-stage Alzheimer disease.

Neurology News Network. for the week ending November 9, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 15, 2024.

The software, designed using thousands of brain MRI scans, is used for automated detection and severity grading of ARIA-E and ARIA-H for safety monitoring of new Alzheimer disease therapies.

Neal K. Shah, CEO at CareYaya Health Technologies, shared his perspective on how the new administration could unleash innovation in neurotech, reduce regulatory barriers with Elon Musk’s involvement, and accelerate innovations that could improve neurological care for those with Alzheimer and dementia.

The professor of neurology and radiology at University of California, San Francisco talked about how the new appropriate use recommendations of donanemab aims to safely integrate this anti-amyloid antibody into the clinical practice. [WATCH TIME: 7 minutes]

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.

The CEO at C2N Diagnostics talked about the clinical utility of the company’s PrecivityAD2 test, which uses the p-tau 217 biomarker and amyloid-β measurements, to increase diagnostic confidence and influence treatment decisions in Alzheimer disease. [WATCH TIME: 7 minutes]

The chief operating officer at Quanterix Corporation talked about pioneering ultra-sensitive blood biomarkers for Alzheimer clinical diagnosis, aiming to enhance detection of brain-derived tau and amyloid status with innovative assays. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of October 2024, compiled all into one place by the NeurologyLive® team.

Neurology News Network. for the week ending November 9, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 8, 2024.

The professor of neuropathology at the University of Tokyo School of Medicine talked about the latest data on lecanemab use in clinical practice for Alzheimer disease in Japan presented at CTAD 2024. [WATCH TIME: 4 minutes]

Nina Miolane, PhD, and Amy Kuceyeski, PhD, the codirectors of the Ann S. Bowers Women's Brain Health Initiative AI Core, provided their commentary on the challenges and progress made in women’s neurology.

The head of global clinical development for immunology/bone at UCB talked about findings presented at CTAD 2024 from the phase 2 trial assessing bepranemab in Alzheimer disease. [WATCH TIME: 3 minutes]

The vice president of scientific engagement at the Alzheimer's Association talked about the emergence of blood biomarker tests as valuable diagnostic tools for Alzheimer disease in the clinical setting. [WATCH TIME: 5 minutes]

The cAPPricorn-1 Phase 2 trial will assess mivelsiran’s efficacy in CAA, focusing on reducing the annualized rate of new cerebral microbleeds over 24 months.

The professor of psychiatry and pharmacology at the University of Toronto talked about results from a post hoc analysis presented at CTAD 2024 that explored synthetic cannabinoid nabilone for agitation in Alzheimer disease. [WATCH TIME: 4 minutes]

A trio of experts from Sinaptica Therapeutics talked about recent findings presented at CTAD 2024 from a study assessing personalized transcranial magnetic stimulation in patients with Alzheimer disease. [WATCH TIME: 5 minutes]

Using a Brain-Chip model, investigators demonstrated that pepinemab can inhibit or reverse damage from toxic alpha-synuclein aggregates, with similar results for amyloid-ß expected soon.